{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-137586","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2022-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.892408+00:00","generated_at":"2026-06-26T01:34:00.416189+00:00","sec_items":["2.05","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Spero halts tebipenem HBr commercialization, cuts workforce 75%; shifts focus to SPR720/SPR206","bullets":["Immediately stopping tebipenem HBr commercialization after FDA indicated insufficient data for approval in current review cycle.","Workforce reduction of ~75% (from 146 to ~35 FTEs); expects ~$8M in severance costs in Q2 2022.","COO Cristina Larkin and CMO David Melnick separating; both to receive severance and remain as consultants for 10 months.","Focus shifts to Phase 2-ready programs SPR720 (NTM lung disease) and SPR206 (MDR Gram-negative infections).","Cash runway extended through late 2023; $146.4M in cash at Dec 31, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-137586","json":"https://secwatch.observer/filing/0001193125-22-137586.json","markdown":"https://secwatch.observer/filing/0001193125-22-137586.md","text":"https://secwatch.observer/filing/0001193125-22-137586.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312522137586/0001193125-22-137586-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312522137586/d241547d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T01:34:00.416189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"32497e2321","claim":"Cristina Larkin departed as Chief Operating Officer at Spero Therapeutics, Inc..","evidence_excerpt":"Chief Operating Officer Effective as of July 2, 2022 (the \"Effective Date\"), Cristina Larkin will separate from the Company as its Chief Operating Officer pursuant to the Restructuring.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312522137586/0001193125-22-137586-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"3a3acb618f","claim":"David Melnick departed as Chief Medical Officer at Spero Therapeutics, Inc..","evidence_excerpt":"Chief Medical Officer Effective as of the Effective Date, David Melnick, M.D. will separate from the Company as its Chief Medical Officer pursuant to the Restructuring.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312522137586/0001193125-22-137586-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}